MDIIM Thought Leadership Event: Balancing Research Excellence with Impact

Event

Donald E. Armstrong Building Room 375, 3420 rue McTavish, Montreal, QC, H3A 3L1, CA
Price: 
Free with registration

​Prof. André Spicer has become a notable management research figure – regularly called upon by major media outlets as an expert commentator, but more often making the news through his own social media accounts and unconventional initiatives. His research has gained popularity in the public sphere all while balancing a successful academic career.

McGill faculty are invited to a seminar and discussion with Professor Spicer to hear his experience and strategies for identifying impactful research topics that appeal to both traditional and contemporary media. Participants will be encouraged to think about impact beyond media in influencing government policy, organizational practice, activism, and teaching, all while balancing the many responsibilities of academic life.

André Spicer is Professor of Organisational Behaviour and the founding director of ETHOS: The Centre for Responsible Enterprise at Cass Business School, City, University of London. Prof. Spicer has become a regular figure in global media and is a frequent commentator in outlets including the Financial Times, CNN, BBC, CNBC, Channel Four, The Guardian, The Wall Street Journal, The Washington Post, The Times, Telegraph, Independent and many others. He has also published several books 'Contesting the Corporation' (Cambridge), 'Unmasking the Entrepreneur' (Edward Elgar), 'Understanding Organizations' (Sage), 'Metaphors We Lead By' (Routledge), 'The Wellness Syndrome' (Polity), and most recently ‘Business Bullshit’ (Routledge). 

Confirmation of attendance is appreciated by Tuesda, May 22, 2018. Kindly RSVP or send questions to mdiim.mgmt [at] mcgill.ca (subject: Andre%20Spicer%20Seminar)  

Coronavirus (COVID-19)

Get the latest Covid-19 updates and learn what to expect for McGill’s return to campus this Fall, 2021.

For Desautels specific updates please visit our COVID-19 FAQ page.

Back to top